The first launch of Qingke Bio received another round of financing of 400 million yuan to accelerate the construction of a ＂gene factory＂

This round of financing is mainly used for R&D investment, technology platform upgrade and talent team expansion of Qingke Biogene Factory, as well as promoting the layout of international operation, so as to create an intelligent and automated production platform that meets global standards. Kaicheng Capital and Huasheng Capital acted as financial advisers of Qingke Bio in this transaction.

In May, 2022, the national "14th Five-Year Plan" sounded the clarion call to enter the era of "bio-economy". Put forward in the planAccelerate the improvement of biotechnology innovation ability, accelerate the wide empowerment of health, agriculture, energy, environmental protection and other industries by biotechnology, and promote the diversified development of bio-economy. Among them, gene synthesis, as an important bottom enabling technology of bio-economy, will play a key role in promoting and promoting technology. According to the forecast of Innovation Drive Center of National Development and Reform Commission, by 2025, the total amount of bio-economy is expected to reach 22 trillion RMB.As the basic unit of life genetic material,In the era of bio-economy, genes reshape the world, change the production and lifestyle of human beings, and realize the cross-border integration of biology, information and materials. The demand for enabling technology gene synthesis in the whole industry has increased significantly. According to the report Oligo Nucleotide Synthesis Market 2021 published by Markets and Markets Research, it is predicted that global gene synthesis.Its market size will exceed 100 billion RMB in 2026.

Beijing Qingke Biotechnology Co., Ltd. (Tsingke Biotechnology Co., Ltd.) is an independent platform-based enterprise for gene synthesis in the whole industrial chain, and its business scope covers three major directions: synthetic genomics products and services, raw materials and equipment for life sciences, and biological manufacturing CXO. Qingke Biology integrates raw materials, synthetic instruments and equipment, synthetic technology and services, and realizes the self-aggregation of production factors in gene factory. It is in the forefront of the domestic industry in the construction of the whole industrial chain of gene synthesis, and has obvious technical and cost advantages. Based on the innovative genetic intelligent molecular resolution and assembly technology, combined with AI algorithm of TSINGKE HELIXTECH, Qingke Bio has built an intelligent production line by connecting raw materials, equipment and technology in series, and achieved low-cost, high-efficiency and high-quality synthetic services through accurate genetic testing and quality inspection technology.In terms of service network, Qingke Bio is currently building in China.8 wholly-owned subsidiaries, 1 holding subsidiary and 17Home branch, builtStrong network system and proprietary logistics system, covering more than 80% of major cities in China, Europe, America, Southeast Asia and other markets, have the ability to quickly respond to customer needs and provide products and services to nearly 200,000 users around the world.

Steady development is the main theme of Qingke Bio. After the A round of financing, Qingke Bio has made a series of major milestones, including the signing of a strategic cooperation agreement for the synthesis of hundreds of millions of small nucleic acids, the commissioning of the new factory of molecular reagents in Qingke, Hubei, the commissioning of the self-developed Oligo automatic synthesis production line in Tianjin and the commissioning of Suzhou Zixi modified probe production base. In addition, Qingke Bio has carried out in-depth cooperation with Academician Zheng Yuguo, and with the advantage of gene synthesis, it is deeply involved in synthetic bio-manufacturing.

Ma Shijin, founder, chairman and general manager of Qingke Bio, said: I am very grateful to all professional investment institutions for their recognition and support. Since the establishment of the company, we have aimed at the huge development space of gene synthesis industry and firmly taken the road of independent research and development and integrated innovation. The development path of the company, in a nutshell, is the development path from "synthesis technology" to "synthesis platform" and then to the intelligent "gene production factory" independently built by all production factors. Over the years, the development of bio-economy and life sciences has promoted the rapid growth of Qingke, and the innovative technology, scale advantage and cost advantage of Qingke’s biology have also continued to feed back the development of the industry. Du Jun, vice president of strategy and technology, also said that this round of financing will further promote the company’s technological innovation of Qualcomm, high-capacity and high-quality gene synthesis from the strategic level, focusing on cultivating and arranging the capacity and system construction of biomedical application fields in the direction of small nucleic acid drugs, CGT and bio-manufacturing.

Dr. Ge Dangqiao, deputy general manager of Huirong Fund of Henan Investment Group, said: Henan Investment Group has actively laid out the bio-industry in recent years. In 2022, the Henan Emerging Industry Guidance Fund we managed also set up a special sub-fund for synthetic biology with a target scale of 1.5 billion yuan. As a platform enterprise in the field of gene synthesis, Qingke Bio is located in the upstream of the bio-industry, providing basic technology and services for the whole industry and playing the role of "water seller", which is the supporting force for the future explosion of synthetic biology and gene therapy industry. More importantly, Qingke Bio pays attention to improving its independent innovation ability, realizes the layout of the whole industrial chain, and grasps the opportunities brought by the acceleration of biomedical industry, synthetic bio-manufacturing and domestic substitution of core equipment. The future business expansion is imaginative and the market space is limitless.

Dr. Xu Yuanping, managing director of Dachen Caizhi, said: As an investment institution that has been deeply involved in the medical and health field for many years, we will pay more attention to the underlying logic of industry growth. Looking forward to the future, in the field of life sciences, whether it is research, diagnosis, treatment or manufacturing, it will fully enter the molecular era dominated by genes. As a banner of the gene synthesis industry, Qingke Bio has advanced independent research and development capabilities (synthetic raw materials, synthetic instruments and equipment, synthetic technology), solid precipitation and leading layout all play an important role in the company’s development.

Zhou Lixin, managing director of Kailian Capital, said: Qingke Bio not only has a leading scale advantage in the gene synthesis industry, but also fully covers the gene synthesis technology. At the same time, Qingke Bio has long been based on independent research and development of synthetic instruments, raw materials and carriers, separation and purification technology and automated production lines. The technology and equipment achievements accumulated over the years will eventually help enterprises achieve multi-scenario business coverage, with huge room for expansion.

Dr. Sui Xiao, Chairman of Qingsong Capital, said: Qingsong Capital focuses on medical and health industries, and Qingke Bio has built a perfect gene synthesis platform by virtue of the advantages of the whole industrial chain of gene synthesis. We are very optimistic about them and hope that through empowering enterprises, Qingke can be boosted to speed up its listing.

Wang Wenli, general manager of the investment banking division of Zhongyuan Assets, said: Zhongyuan Assets is committed to serving the real economy, and hopes to serve Henan’s industrial development by investing in a platform-based enterprise such as Qingke Bio and grafting advanced technology and scientific research teams.

Dong Wang, a partner of Jinyu Maowu, said: The medical and pharmaceutical health industry is one of the core investment fields of Jinyu Maowu for a long time, and it is a great honor to participate in this round of financing of Qingke Bio. During our visit to industry customers, Qingke’s product quality and service efficiency were highly praised by customers. Among these customers who have a good reputation, Qingke can continue to develop new business cooperation, which has great potential. We are very optimistic about this virtuous circle and decreasing marginal cost business model. Under the leadership of management, Qingke Bio will surely make new breakthroughs.

Dr. Zou Guowen, founder of Kaicheng Capital, said: Qingke Bio is an intelligent gene factory platform integrating raw material production, synthetic equipment and process development and automatic production in China, with advanced design, synthesis and assembly technology and gene synthesis platform system, covering multi-level product layout, strong service network system and experienced management team with super execution. We believe that Qingke Bio will further develop its advantages through the "gene factory" and make continuous breakthroughs, providing the driving force for the development of biomedicine, bio-manufacturing and environmental protection.

In the future, Qingke Bio will further increase investment in technology research and development, give play to the advantages of intelligent, customized and large-scale gene factories, and accelerate the expansion of gene factories in differentApplication of scene, contributing to life sciences, medical and health industries.